{"id":51082,"date":"2022-11-21T16:02:03","date_gmt":"2022-11-21T15:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-worldwide-mycoplasma-testing-industry-is-expected-to-reach-2-2-billion-by-2030-researchandmarkets-com\/"},"modified":"2022-11-21T16:02:03","modified_gmt":"2022-11-21T15:02:03","slug":"the-worldwide-mycoplasma-testing-industry-is-expected-to-reach-2-2-billion-by-2030-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-worldwide-mycoplasma-testing-industry-is-expected-to-reach-2-2-billion-by-2030-researchandmarkets-com\/","title":{"rendered":"The Worldwide Mycoplasma Testing Industry is Expected to Reach $2.2 Billion by 2030 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Mycoplasma Testing Market Size, Share & Trends Analysis by Product (Instruments, Kit & Reagents), by Technology (PCR, ELISA), by Application (Cell Line Testing, Virus Testing), by End Use, Region and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global mycoplasma testing market size is expected to reach USD 2.2 billion by 2030. The market is expected to expand at a CAGR of 13.2% from 2022 to 2030.\n<\/p>\n

\nThe major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market’s overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.\n<\/p>\n

\nGrowing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method.\n<\/p>\n

\nThese changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.\n<\/p>\n

\nThe rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic’s stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market’s growth.\n<\/p>\n

\nIncreasing investments in R&D have contributed significantly to the market’s revenue growth. With rising healthcare expenditure, research activities in the life sciences industry are increasing significantly. The adoption of new technologies for drug discovery & development and innovations in cell culture technologies are driving the demand for mycoplasma tests. The high risk of cell culture contamination remains the primary factor expected to drive the mycoplasma testing market over the forecast period\n<\/p>\n

\nMycoplasma is estimated to contaminate around 15%-35% of all continuous cell cultures around the world. Out of over 190 known species of mycoplasma, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for an increase in the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.\n<\/p>\n

\nMycoplasma Testing Market Report Highlights<\/strong>\n<\/p>\n